ENTRADA THERAPEUTICS, INC. Total Liabilities
ENTRADA THERAPEUTICS, INC. (TRDA) had Total Liabilities of $65.47 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-05
- 2026-06-30: Liabilities $65.47M.
- 2026-03-31: Liabilities $64.66M.
- 2025-12-31: Liabilities $71.25M.
- 2025-09-30: Liabilities $72.18M.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $65.47M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $64.66M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $71.25M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $72.18M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $69.28M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $69.22M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $97.64M 10-K · filed 2026-02-26 |
| 2024-09-30 | $132.14M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $152.04M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $241.48M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $226.83M 10-K · filed 2025-02-27 |
| 2023-09-30 | $238.37M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $287.07M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $245.96M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $39.50M 10-K · filed 2024-03-13 |
| 2022-09-30 | $41.24M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $39.88M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $39.31M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $7.12M 10-K · filed 2023-03-06 |
| 2021-09-30 | $7.50M 10-Q · filed 2021-12-09 |
| 2020-12-31 | $3.36M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |